Baseline Characteristics (n = 268)
| No. of patients | ||
| Characteristic | Yes | No |
| Male | 138 (52) | 130 (49) |
| Primary tumor | ||
| Pancreatic NET | 72 (27) | |
| Nonfunctional | 61 (85) | |
| Functional | 11 (15) | |
| Gastrointestinal or thoracic NET | 178 (66) | |
| Foregut | 22 (12) | |
| Midgut | 145 (82) | |
| Hindgut | 11 (6) | |
| Unknown | 18 (7) | |
| Previous therapy | 203 (76) | 65 (24) |
| Octreotide | 142 (53) | 126 (47) |
| Surgery | 118 (44) | 150 (56) |
| Chemotherapy | 26 (10) | 242 (90) |
| Radiotherapy | 10 (4) | 258 (96) |
| Liver metastases | 237 (88) | 31 (12) |
| Bone metastases | 55 (21) | 213 (80) |
| Tumor uptake on Octreoscan | ||
| Equal to normal liver | 9 (3) | |
| >Normal liver | 194 (72) | |
| >Kidneys | 65 (24) | |
Baseline characteristics of Dutch patients with gastroenteropancreatic or thoracic NET who had been treated with 177Lu-octreotate according to protocol between January 2000 and April 2007. Mean age (y) was 59 (age range, 23–83 y); median administered dose in GBq was 29.6 (range, 7.4–30.7 GBq). Data in parentheses are percentages.